Search research articles
Contact Us
Filters
Showing results (491-500 of 713) with videos related to
Page
of 72
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 22, 2004
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls
Hagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 24, 2013
Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia
Paolo Strati, Naval Daver, Farhad Ravandi, et al.
Leukemia & Lymphoma
|
August 10, 2013
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience
Ohad Benjamini, Hagop Kantarjian, Mary Beth Rios, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 21, 2014
Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia
Stefan Faderl, Kumudha Balakrishnan, Deborah A Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 8, 2004
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia
Francis Giles, Deborah Thomas, Guillermo Garcia-Manero, et al.
Blood
|
January 13, 2006
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
Stefan Faderl, Srdan Verstovsek, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 27, 2012
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia
Elias Jabbour, Guillermo Garcia-Manero, Jorge Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2009
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment
William G Wierda, Susan O'Brien, Xuemei Wang, et al.
British Journal of Haematology
|
February 6, 2016
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes
Preetesh Jain, Hagop Kantarjian, Koji Sasaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2005
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
Mirna Golemovic, Srdan Verstovsek, Francis Giles, et al.
Page
of 72
Search research articles
Search
Showing results (491-500 of 713) with videos related to
Sort By:
Page
of 72
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 22, 2004
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls
Hagop Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 24, 2013
Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia
Paolo Strati, Naval Daver, Farhad Ravandi, et al.
Leukemia & Lymphoma
|
August 10, 2013
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience
Ohad Benjamini, Hagop Kantarjian, Mary Beth Rios, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 21, 2014
Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia
Stefan Faderl, Kumudha Balakrishnan, Deborah A Thomas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 8, 2004
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia
Francis Giles, Deborah Thomas, Guillermo Garcia-Manero, et al.
Blood
|
January 13, 2006
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
Stefan Faderl, Srdan Verstovsek, Jorge Cortes, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 27, 2012
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia
Elias Jabbour, Guillermo Garcia-Manero, Jorge Cortes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2009
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment
William G Wierda, Susan O'Brien, Xuemei Wang, et al.
British Journal of Haematology
|
February 6, 2016
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes
Preetesh Jain, Hagop Kantarjian, Koji Sasaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 8, 2005
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
Mirna Golemovic, Srdan Verstovsek, Francis Giles, et al.
Page
of 72